TLDR: Insilico Medicine, a leader in AI-driven drug discovery, is set to unveil its latest generative AI platform and present cutting-edge research on pulmonary fibrosis at the Pulmonary Fibrosis Foundation (PFF) Summit 2025 in Chicago. This announcement highlights the company’s continued advancements in leveraging artificial intelligence to accelerate drug discovery, improve disease understanding, and develop novel therapeutics, including a significant partnership with Eli Lilly valued at over $100 million.
Insilico Medicine, a pioneering force in the convergence of artificial intelligence and biomedical research, is preparing to make significant announcements at the upcoming Pulmonary Fibrosis Foundation (PFF) Summit 2025, scheduled from November 13-15 in Chicago, Illinois. The company is poised to unveil its advanced generative AI platform, alongside presenting groundbreaking findings from its AI-driven research into pulmonary fibrosis. This event underscores Insilico Medicine’s commitment to transforming drug discovery and development through innovative AI technologies.
The PFF Summit 2025, a premier global forum for specialists in pulmonary fibrosis (PF) and interstitial lung disease (ILD), will serve as the stage for Insilico Medicine to demonstrate how its generative AI platform is accelerating the identification of novel drug candidates and enhancing the understanding of complex diseases like pulmonary fibrosis. The company’s presentation will specifically highlight its AI-designed Rentosertib, a TNIK inhibitor, and its therapeutic advancements for idiopathic pulmonary fibrosis. This research exemplifies the power of AI in streamlining the journey from molecular design to patient benefit.
Insilico Medicine’s technological prowess extends through its proprietary Pharma.AI ecosystem, which integrates AI agents, advanced Large Language Models (LLMs), and automated laboratory robotics. This multifaceted approach is exemplified by Life Star1, the company’s sixth-generation automated laboratory system, which dramatically accelerates experimental feedback loops crucial for optimizing drug candidates. The continuous evolution of this platform signals a future where AI-generated hypotheses are rapidly validated or refined in fully integrated wet lab environments.
Further solidifying its position as an industry leader, Insilico Medicine recently announced a deepened research collaboration with Eli Lilly. This strategic partnership, valued at over $100 million including an upfront payment, milestone payments, and tiered royalties, will see Insilico apply its Pharma.AI platform to design and optimize novel therapeutic candidates. Alex Zhavoronkov, PhD, Founder and Co-CEO of Insilico Medicine, expressed enthusiasm for the collaboration, stating, “We are delighted to collaborate with Lilly, a global leader in the pharmaceutical industry, renowned for its commitment to medical innovation. Lilly has been a valued user of our Pharma.AI software suite, and this expanded collaboration further recognizes Insilico’s AI-driven drug discovery capabilities while strengthening our longstanding partnership. By joining forces, we are accelerating the development of transformative therapies to address urgent patient needs worldwide.” This partnership builds upon an existing AI-based software licensing agreement from 2023.
Also Read:
- Xunming Biotech Secures Multi-Million Series A Funding to Advance AI-Powered Antibody Design
- China Dominates Global Generative AI Patent Landscape (2014-2023), Outpacing US Sixfold
Insilico Medicine’s impact is also recognized by its inclusion in Nature Index’s “2025 Research Leaders,” which ranks the top 100 global corporate institutions for biological and natural sciences publications. Beyond pulmonary fibrosis, the company has also unveiled AI-developed drug candidates for cardiometabolic diseases at BIO Europe 2025, showcasing the versatility and broad applicability of its AI-powered optimization methods across various therapeutic areas. These developments underscore Insilico Medicine’s role as a frontrunner in leveraging AI to address critical challenges in global health.
